表紙
市場調查報告書
商品編碼
1069447

癌症微生物基因體定序的全球市場:現狀分析與預測(2021年∼2027年)

Cancer Microbiome Sequencing Market: Current Analysis and Forecast (2021-2027)

出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 252 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球癌症微生物基因體定序的市場規模,在預測期間(2021年∼2027年)預計將以約20%的年複合成長率成長。

越來越重視微生物組在癌症領域的潛力以及全球癌症發病率的激增是市場成長的因素之一,此外,行業參與者之間為加速微生物組研究建立戰略聯盟是另一個顯著推動全球癌症微生物組測序市場的重要因素。

本報告提供全球癌症微生物基因體定序市場的相關調查,提供市場摘要,市場洞察,市場機會,競爭模式,企業概要等全面性資訊。

目錄

第1章 市場簡介

  • 市場定義
  • 調查的目的
  • 限制
  • 相關利益者
  • 報告所使用的貨幣
  • 全球癌症微生物基因體定序調查範圍

第2章 調查手法或假設

  • 全球癌症微生物基因體定序市場調查手法
    • 全球癌症微生物基因體定序市場主要目的

第3章 市場摘要

第4章 摘要整理

第5章 COVID-19影響

第6章 全球癌症微生物基因體定序市場收益

第7章 市場洞察:各報價環

  • 產品
    • 套件和化驗
    • 軟體
  • 服務

第8章 市場洞察:各技術

  • 下一代序列
    • 合成定序
    • 連接測序
    • 其他
  • 聚合酵素鏈鎖反應

第9章 市場洞察:各應用領域

  • 大腸癌
  • 子宮頸癌
  • 口腔癌
  • 其他

第10章 市場洞察:各終端用戶

  • 學術機構·研究機關
  • 製藥及生物科技企業
  • 醫院及診斷實驗室
  • 其他

第11章 市場洞察:各地區

  • 北美的癌症微生物基因體定序市場
    • 美國
    • 加拿大
    • 其他的北美
  • 歐洲的癌症微生物基因體定序市場
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他的歐洲
  • 亞太地區的癌症微生物基因體定序市場
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他的亞太地區
  • 其他

第12章 癌症微生物基因體定序市場市場動態

  • 推動市場要素
  • 市場課題
  • 影響分析

第13章 癌症微生物基因體定序的市場機會

第14章 癌症微生物基因體定序市場趨勢與洞察

第15章 相關法規

第16章 需求與供給面的分析

  • 需求面分析
  • 供給面分析
    • 主要產品的銷售
    • 主要企業的夥伴關係
    • 主要的合併和收購

第17章 價值鏈分析

第18章 競爭模式

  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 產業的競爭
    • 替代品的可得性
    • 新加入廠商業者的威脅
  • 競爭情形
    • 企業佔有率:各收益

第19章 企業概要

  • Thermo Fisher Scientific Inc.
    • 重要的事實
    • 營業內容
    • 主要的產品/提供的服務
    • 成長策略
    • SWOT分析
    • 主要財務
    • 最近的開發
  • CD Genomics
  • Eurofins Scientific
  • Illumina, Inc.
  • Prescient Medicine Holdings, Inc.
  • QIAGEN N.V.
  • Micronoma Inc.
  • Oxford Nanopore Technologies
  • Zymo Research Corporation
  • OraSure Technologies, Inc.

第20章 免責聲明

目錄
Product Code: UMHE21725

Global Cancer Microbiome Sequencing Market is anticipated to grow with an elevated CAGR of around 20% over the forecast period (2021-2027). The microbiome is the collection of all the gene sequences from a microbial community in the human body that contributes to human health and the body. Sequencing allows the profiling of microbial communities that may be targeted for developing new therapeutic approaches to cancer.

The cancer microbiome sequencing market has been growing on account of various factors including the growing emphasis on the microbiome's potential in the field of cancer and surging incidences of cancer across the globe. For instance, the number of cancer cases in the US will increase 49% each year, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years, as per the predictions by CDC. This exponential increase in cancer prevalence has created a buzz among biotechnology companies for investing in the development of novel diagnostic tools based on the microbiome that will offer early cancer detection.

Additionally, promulgating strategic alliances among industry players for accelerating microbiome research is another prominent factor that is significantly driving the cancer microbiome sequencing market globally. For example, in June 2021, Illumina and Microba Life Sciences came into a partnership to advance their understanding of the human gut microbiome in human health and disease. Illumina's revolutionary NGS tools and Microba's high-quality proprietary gut microbiome analysis platform will generate the accurate metagenomic data that researchers require to fuel discoveries.

Thermo Fisher Scientific Inc., CD Genomics, Eurofins Scientific, Illumina, Inc., Prescient Medicine Holdings, Inc., QIAGEN N.V., Micronoma Inc., Oxford Nanopore Technologies, Zymo Research Corporation, OraSure Technologies, Inc., are some of the prominent players operating in the cancer microbiome sequencing market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with cancer microbiome sequencing products.

Insights Presented in the Report

"Amongst Offerings, products segment holds the major share"

Based on offerings, the cancer microbiome sequencing market is divided into products & services. The products segment accounted for the leading market share in 2020 it is estimated that it will exhibit the highest CAGR during the forecast. The products segment is further sub-segmented into kits & assays and software. The growth of this segment can be attributed to the rising number of sequencing procedures and the launch of new and advanced assay kits and software. However, the services segment is expected to grow considerably during the projected timeframe.

"Amongst Technology, next-generation sequencing segment holds the major share"

Based on technology, the cancer microbiome sequencing market is segmented into next-generation sequencing (NGS) and polymerase chain reaction. The next-generation sequencing segment occupied a substantial share of the cancer microbiome sequencing market in 2020 and it is expected to grow considerably in the upcoming years as NGS allows clinicians to test various cancer genes simultaneously. Furthermore, the growing adoption of next-generation sequencing in clinical oncology to advance personalized cancer treatment is also contributing to the growth of the segment.

"Amongst Application, colorectal cancer segment holds the major share"

Based on application, the market is fragmented into colorectal cancer, cervical cancer, oral cancer, and others. In 2020, the colorectal cancer segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. The growth of this segment is attributed to the rising incidences of colorectal cancer globally. For instance, according to the report by the International Agency for Research on Cancer, the incidences of colon cancer were nearly 1.1 million in 2019 and it is expected to increase to over 1.5 million by 2030.

"Amongst End-Users, hospitals & diagnostic laboratories segment holds the major share"

Based on end-users, the market is fragmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and others. In 2020, the hospitals & diagnostic laboratories segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period as the majority of the sequencing test takes place in laboratories for detecting various diseases. However, the academic & research institutes segment is expected to grow significantly in the upcoming years.

"North America represents one of the largest markets of cancer microbiome sequencing market"

For a better understanding of the market dynamics of the cancer microbiome sequencing market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the cancer microbiome sequencing market industry and generated revenue of USD XX Million in 2020 owing to growing healthcare expenditure and the presence of industry players in the region. Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The global cancer microbiome sequencing market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1 Market Definitions
  • 1.2 Objective of the Study
  • 1.3 Limitation
  • 1.4 Stake Holders
  • 1.5 Currency Used in Report
  • 1.6 Scope of the Global Cancer Microbiome Sequencing Study

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1 Research Methodology for the Global Cancer Microbiome Sequencing Market
    • 2.1.1 Main Objective of the Global Cancer Microbiome Sequencing Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 GLOBAL CANCER MICROBIOME SEQUENCING MARKET REVENUE

7 MARKET INSIGHTS BY OFFERINGS

  • 7.1 Products
    • 7.1.1 Kits & Assays
    • 7.1.2 Software
  • 7.3 Services

8 MARKET INSIGHTS BY TECHNOLOGY

  • 8.1 Next-Generation Sequencing
    • 8.1.1 Sequencing by Synthesis
    • 8.1.2 Sequencing by Ligation
    • 8.1.3 Others
  • 8.2 Polymerase Chain Reaction

9 MARKET INSIGHTS BY APPLICATION

  • 9.1 Colorectal Cancer
  • 9.2 Cervical Cancer
  • 9.3 Oral cancer
  • 9.4 Others

10 MARKET INSIGHTS BY END-USERS

  • 10.1 Academic and Research Institutes
  • 10.2 Pharmaceutical and Biotechnology Companies
  • 10.3 Hospitals and Diagnostic Laboratories
  • 10.4 Others

11 MARKET INSIGHTS BY REGION

  • 11.1 NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Rest of North America
  • 11.2 EUROPE CANCER MICROBIOME SEQUENCING MARKET
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 United Kingdom
    • 11.2.4 Spain
    • 11.2.5 Italy
    • 11.2.6 Rest of Europe
  • 11.3 ASIA PACIFIC CANCER MICROBIOME SEQUENCING MARKET
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 Australia
    • 11.3.5 Rest of Asia Pacific
  • 11.4 REST OF THE WORLD CANCER MICROBIOME SEQUENCING MARKET

12 CANCER MICROBIOME SEQUENCING MARKET DYNAMICS

  • 12.1 Market Drivers
  • 12.2 Market Challenges
  • 12.3 Impact Analysis

13 CANCER MICROBIOME SEQUENCING MARKET OPPORTUNITIES

14 CANCER MICROBIOME SEQUENCING MARKET TRENDS & INSIGHTS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

  • 16.1 Demand Side Analysis
  • 16.2 Supply Side Analysis
    • 16.2.1 Top Product Launches
    • 16.2.2 Top Business Partnerships
    • 16.2.3 Top Merger & Acquisitions

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

  • 18.1 Porter's Five forces analysis
    • 18.1.1 Bargaining power of Supplier
    • 18.1.2 Bargaining power of Buyer
    • 18.1.3 Industry Rivalry
    • 18.1.4 Availability of Substitute
    • 18.1.5 Threat of new Entrants
  • 18.2 Competitive Landscape
    • 18.2.1 Company Shares, By Revenue

19 COMPANY PROFILED

  • 19.1 Thermo Fisher Scientific Inc.
    • 19.1.1 Key Facts
    • 19.1.2 Business Description
    • 19.1.3 Key Product/Services Offerings
    • 19.1.4 Growth Strategy
    • 19.1.5 SWOT Analysis
    • 19.1.6 Key Financials
      • 19.1.6.1 Revenue Split
      • 19.1.6.2 Financial Overview of Thermo Fisher Scientific Inc.
    • 19.1.7 Recent Developments
      • 19.1.7.1 Product Launch
      • 19.1.7.2 Partnerships
      • 19.1.7.3 Business Expansion and Investments
      • 19.1.7.4 Merger and Acquisition
  • 19.2 CD Genomics
  • 19.3 Eurofins Scientific
  • 19.4 Illumina, Inc.
  • 19.5 Prescient Medicine Holdings, Inc.
  • 19.6 QIAGEN N.V.
  • 19.7 Micronoma Inc.
  • 19.8 Oxford Nanopore Technologies
  • 19.9 Zymo Research Corporation
  • 19.10 OraSure Technologies, Inc.

20 DISCLAIMER